See more : Chill Brands Group PLC (CHBRF) Income Statement Analysis – Financial Results
Complete financial analysis of Greenwich LifeSciences, Inc. (GLSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Greenwich LifeSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Infrastrutture Wireless Italiane S.p.A. (0R8S.L) Income Statement Analysis – Financial Results
- Navigator Global Investments Limited (NGI.AX) Income Statement Analysis – Financial Results
- Prakit Holdings Public Company Limited (PRAKIT.BK) Income Statement Analysis – Financial Results
- Maronan Metals Limited (MMA.AX) Income Statement Analysis – Financial Results
- VRL Logistics Limited (VRLLOG.NS) Income Statement Analysis – Financial Results
Greenwich LifeSciences, Inc. (GLSI)
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| Gross Profit | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.70M | 6.48M | 3.56M | 1.06M | 2.61M | 1.27M | 1.22M |
| General & Administrative | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.63M | 1.56M | 1.04M | 806.19K | 818.89K | 419.64K | 346.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Cost & Expenses | 9.33M | 8.04M | 4.60M | 1.86M | 3.43M | 1.69M | 1.57M |
| Interest Income | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K | 3.61K |
| EBITDA | -9.32M | -8.04M | -4.59M | -1.86M | -3.42M | -1.69M | -1.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.33M | -8.04M | -4.60M | -1.86M | -3.43M | -1.69M | -1.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 436.06K | 215.02K | 27.37K | 832.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -8.89M | -7.83M | -4.57M | -1.86M | -3.43M | -1.69M | -1.57M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -215.02K | -27.37K | -832.00 | 3.00 | -157.53K | 3.00 |
| Net Income | -8.89M | -7.61M | -4.54M | -1.86M | -3.43M | -1.69M | -1.57M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| EPS Diluted | -0.69 | -0.59 | -0.35 | -0.15 | -0.29 | -0.14 | -0.13 |
| Weighted Avg Shares Out | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
| Weighted Avg Shares Out (Dil) | 12.85M | 12.91M | 12.94M | 12.70M | 11.74M | 11.97M | 11.74M |
Greenwich LifeSciences: A First Look
Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in...
Follow the Insiders and Buy the Dip in These 3 Stocks
These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.
Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential
Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences...
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Stocks appeared first on InvestorPlace.
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
3 Stocks Insiders Are Buying on Market Turbulence
When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely.
Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings
Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did not receive trastuzumab after surgery.
The Moonshot Investor: The Insider Track Strategy
Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung's Moonshot Investor series. Investors interested in finding stocks with 100x potential or more can subscribe to Tom's mailing list here.
A Controversial Moonshot Stock Just Got a Lot More Interesting
Studies have found that insiders outperform the market by 6-15%. Over a long period, that's an incredible achievement and worth understanding.
3 Stocks Insiders Are Snapping Up. Do They Know Something We Don't?
Insider trading is heavily regulated, but it still happens, and it's worth paying attention to big moves from insiders for potential profits. The post 3 Stocks Insiders Are Snapping Up.
Source: https://incomestatements.info
Category: Stock Reports